[1]
|
Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials
Critical Reviews in Oncology/Hematology,
2020
DOI:10.1016/j.critrevonc.2020.102975
|
|
|
[2]
|
Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials
Japanese Journal of Clinical Oncology,
2020
DOI:10.1093/jjco/hyaa170
|
|
|
[3]
|
A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208)
Annals of Surgery,
2019
DOI:10.1097/SLA.0000000000002865
|
|
|
[4]
|
The postoperative peak number of leukocytes after hepatectomy is a significant prognostic factor for cholangiocarcinoma
Molecular and Clinical Oncology,
2019
DOI:10.3892/mco.2019.1827
|
|
|
[5]
|
A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208)
Annals of Surgery,
2019
DOI:10.1097/SLA.0000000000002865
|
|
|
[6]
|
Heterogeneity of Treg/Th17 According to Cancer Progression and Modification in Biliary Tract Cancers via Self-Producing Cytokines
Digestive Diseases and Sciences,
2019
DOI:10.1007/s10620-019-06011-9
|
|
|
[7]
|
Resectable Cholangiocarcinoma: Reviewing the Role of Adjuvant Strategies
Clinical Medicine Insights: Oncology,
2016
DOI:10.4137/CMO.S32821
|
|
|
[8]
|
Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer
Journal of Hepato-Biliary-Pancreatic Sciences,
2015
DOI:10.1002/jhbp.283
|
|
|
[9]
|
Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer
Cancer Chemotherapy and Pharmacology,
2015
DOI:10.1007/s00280-015-2908-3
|
|
|
[10]
|
Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study
Cancer Chemotherapy and Pharmacology,
2014
DOI:10.1007/s00280-014-2543-4
|
|
|
[11]
|
Prognostic impact of tumoral and/or peri-tumoral stromal SPARC expressions after surgery in patients with biliary tract cancer
Journal of Surgical Oncology,
2014
DOI:10.1002/jso.23767
|
|
|